Literature DB >> 19004982

Does an altered leptin axis play a role in obesity among children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency?

Thomas M K Völkl1, Diemud Simm, Antje Körner, Wolfgang Rascher, Wieland Kiess, Jürgen Kratzsch, Helmuth G Dörr.   

Abstract

OBJECTIVE: Congenital adrenal hyperplasia (CAH) patients are at a higher risk to develop obesity. The role of leptin in CAH is still controversial. Our study aimed to evaluate serum levels of leptin, the soluble leptin receptor (sOB-R), and the sOB-R: leptin molar ratios in a cohort of CAH children and adolescents, and their associations with clinical and metabolic parameters.
METHODS: We studied 51 CAH patients, aged 5.6-19.6 years (median 11.8, n=30 females) cross-sectionally. All patients had genetically proven CAH and received standard steroid substitution therapy. Blood specimens were taken after overnight fasting between 0800 and 1000 h. For the analyses of leptin and sOB-R, matched pairs were built with healthy Caucasian patients for sex, Tanner stage (TS), chronologic age (CA), and body mass index (BMI).
RESULTS: BMI and SDS were significantly elevated compared with the reference population. Leptin levels were not different between matched pairs, whereas sOB-R levels were significantly lower in CAH. Consequently, the sOB-R: leptin molar ratios were significantly decreased in CAH. Correlation analyses in CAH patients revealed significant relationship between leptin and CA, TS, BMI, and homeostasis model assessment of insulin resistance. Similar results were obtained for the matched control group. For sOB-R, we found no significant correlation for CA, TS, or BMI in CAH, but we did in the controls. There were significant correlations for androgens within the CAH group. Additional analyses revealed no correlation with steroid medication or metabolic control.
CONCLUSIONS: Our data show that an altered leptin axis with normal serum leptin concentrations but decreased sOB-R serum levels may contribute to the increased risk of overweight and obesity in CAH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004982     DOI: 10.1530/EJE-08-0770

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  14 in total

1.  Obesity in children with congenital adrenal hyperplasia in the Minnesota cohort: importance of adjusting body mass index for height-age.

Authors:  Kyriakie Sarafoglou; Gregory P Forlenza; O Yaw Addo; Jennifer Kyllo; Aida Lteif; P C Hindmarsh; Anna Petryk; Maria Teresa Gonzalez-Bolanos; Bradley S Miller; William Thomas
Journal:  Clin Endocrinol (Oxf)       Date:  2017-03-28       Impact factor: 3.478

2.  Increased Abdominal Adiposity in Adolescents and Young Adults With Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.

Authors:  Mimi S Kim; Anna Ryabets-Lienhard; Anh Dao-Tran; Steven D Mittelman; Vicente Gilsanz; Sheree M Schrager; Mitchell E Geffner
Journal:  J Clin Endocrinol Metab       Date:  2015-06-10       Impact factor: 5.958

Review 3.  Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.

Authors:  Krupali Bulsari; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

Review 4.  Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update.

Authors:  Christine M Trapp; Sharon E Oberfield
Journal:  Steroids       Date:  2011-12-13       Impact factor: 2.668

5.  Carotid intima media thickness and other cardiovascular risk factors in children with congenital adrenal hyperplasia.

Authors:  N H Amr; A Y Ahmed; Y A Ibrahim
Journal:  J Endocrinol Invest       Date:  2014-08-12       Impact factor: 4.256

6.  Cardio-metabolic risk factors in youth with classical 21-hydroxylase deficiency.

Authors:  Kansuda Ariyawatkul; Supatporn Tepmongkol; Suphab Aroonparkmongkol; Taninee Sahakitrungruang
Journal:  Eur J Pediatr       Date:  2017-02-21       Impact factor: 3.183

Review 7.  Clinical outcomes in the management of congenital adrenal hyperplasia.

Authors:  Henrik Falhammar; Marja Thorén
Journal:  Endocrine       Date:  2012-01-07       Impact factor: 3.633

8.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline.

Authors:  Phyllis W Speiser; Ricardo Azziz; Laurence S Baskin; Lucia Ghizzoni; Terry W Hensle; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; Victor M Montori; Sharon E Oberfield; Martin Ritzen; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2010-09       Impact factor: 5.958

Review 9.  Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.

Authors:  Henrik Falhammar; Anna Nordenström
Journal:  Endocrine       Date:  2015-06-17       Impact factor: 3.633

Review 10.  [Congenital adrenal hyperplasia and growth hormone deficiency. Special care in transition to adulthood].

Authors:  H G Dörr; C Schöfl
Journal:  Internist (Berl)       Date:  2009-10       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.